Skip to main content
. 2021 Nov 26;10(23):5551. doi: 10.3390/jcm10235551

Table 1.

Summary of proposed recommended targets of “treat-to-target” approach in UC management.

Treatment Target Targets to Achieve Time to Reassess Targets
Clinical Active Clinical Remission
1. Clinical symptoms

  • PRO2 remission (RB = 0 and SF ≤ 1)

  • Partial Mayo score (<2)

 Mild: 8–12 weeks
Moderate–severe: 2–4 weeks		 Mild: 6–12 months
Moderate–severe: 3–6 months
2. Biomarkers

  • CRP < normal limit

  • FC < 250 μg/g (minimum), <100 μg/g (optimum)

 Mild: 3–6 months
Moderate–severe:
8–12 weeks after therapy initiation 		Mild: 6–12 months
Moderate–severe:
3–6 months
3. Endoscopy (mucosal healing)

  • MES 0 (1, minimum)

  • UCEIS 0 (1, minimum)

 Mild: 6–12 months or if altered symptoms or abnormal biomarkers
Moderate–severe: 3–6 months after therapy initiation (STRIDEI, II)		 Based on screening recommendations in deep remission Prompted by clinical symptoms or (consecutive) biomarker positivity
4. Histology
(histological remission/
response)

  • Nancy histological index (NHI)

  • Geboes score (GS)

  • Robarts histopathology index (RH) (see Table 2)

 Adjunctive (added-on) target Adjunctive (added-on) target